+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 33 Actively Recruiting clinical trials

L

Actively Recruiting

This research aims to evaluate the long-term safety and efficacy of APG777 in adults with moderate-to-severe atopic dermatitis who have already completed treatment in a prior APG777 study. The study is a multicenter, double-blind, phase 2 extension designed for participants who, according to the investigator, could benefit from continued APG777 treatment. The study consists of three periods a Screening Visit coinciding with the last visit of the parent studys Maintenance Period an Extended Treatment Period where participants maintain their APG777 dose from the previous study or receive open-label APG777 if they did not meet certain response criteria and a Post-treatment Follow-up Period. Participants receive APG777 as subcutaneous injections every 12 or 24 weeks, depending on their previous dosing regimen or study arm assignment. During the study, participants will have assessments for safety and efficacy, including monitoring treatment-emergent adverse events for up to 3 years. Researchers will also track improvements in eczema severity, itch symptoms, use of rescue therapy, and serum drug concentrations over an average of 2 years during the Extended Treatment Period. Participation may last up to 3 years, including follow-up to observe long-term outcomes.

Age: 18Years +All GendersPhase 2
80 locations
O

Actively Recruiting

Researchers are conducting a prospective, observational study to assess asthma control, health-related quality of life HRQL, lung function, and medication use in patients with severe eosinophilic asthma who are treated with benralizumab under routine care in Germany. The study aims to observe how these patients manage their asthma over time and how their treatment impacts their daily lives and health status. Participants receive benralizumab as part of their standard care, with no experimental treatment assigned by the study. The study lasts up to 52 weeks and monitors changes in asthma control using tools like the Asthma Control Test ACT and the Asthma Impairment and Risk Questionnaire AIRQ. Health-related quality of life is measured at baseline and follow-ups using the mini Asthma Quality of Life Questionnaire miniAQLQ. Patients also keep a weekly diary of their asthma medication intake, either on paper or electronically, to track any changes. Throughout the study, participants will have assessments at various time points up to one year after starting benralizumab. These include questionnaires on asthma control and quality of life, lung function tests, and biomarker measurements such as eosinophil levels and exhaled nitric oxide. Researchers analyze changes in medication doses and asthma symptoms, while patients regularly report their experiences. The study focuses on real-world outcomes without altering prescribed treatments, aiming to provide insights into the effects of benralizumab in everyday clinical practice.

Age: 18Years - 120YearsAll Genders
41 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
E

Actively Recruiting

Researchers are evaluating AZD0292, a bispecific IgG1k monoclonal antibody, for preventing exacerbations in patients aged 12 years and older with bronchiectasis who are chronically colonized with Pseudomonas aeruginosa PsA. This Phase IIb study compares two intravenous dosage regimens of AZD0292 to placebo, including participants with non-cystic fibrosis bronchiectasis NCFBE and an exploratory group with cystic fibrosis CF bronchiectasis. Participants will receive either a high dose or low dose of AZD0292 or placebo via IV infusion starting on Day 1, with further doses given according to the study schedule. The study uses a randomized, double-blind, placebo-controlled, parallel design to assess the drugs efficacy, safety, and pharmacokinetics. The primary focus is on PsA-colonized bronchiectasis patients who have frequent pulmonary exacerbations, with treatment continuing for a variable follow-up period. During the study, participants will be monitored regularly for exacerbation rates, lung function, quality of life measures, and adverse events. Assessments include sputum cultures, pulmonary function tests, serum pharmacokinetic sampling, and questionnaires like the QOL-B-RSS and SGRQ. Safety monitoring extends up to 24 weeks after the last dose, and the study duration varies from at least 28 weeks to a maximum of 52 weeks of follow-up.

Age: 12Years +All GendersPhase 2
186 locations
R

Actively Recruiting

Researchers are evaluating the efficacy and safety of SAR445399, a drug administered by injection, in adults with moderate to severe hidradenitis suppurativa. This multinational, randomized, double-blind, placebo-controlled Phase 2 study aims to compare two different doses of SAR445399 with a placebo to find the best dose for treating this condition. Participants will be randomly assigned to receive one of two SAR445399 dose regimens or a matching placebo. The treatment period lasts 32 weeks, including a 16-week initial double-blind phase followed by a 16-week treatment-blinded extension period. The total study duration for each participant is up to 46 weeks, with a total of 16 study visits scheduled throughout this time. During the study, participants will be monitored through various assessments including clinical response measures such as Hidradenitis Suppurativa Clinical Response HiSCR levels, severity scoring, skin pain ratings, quality of life questionnaires, laboratory tests, vital signs, and electrocardiograms. Researchers will also track drug concentrations and immune responses. Safety will be closely monitored throughout the study and extension period to evaluate any adverse events or significant changes in health.

Age: 18Years +All GendersPhase 2
86 locations
P

Actively Recruiting

Researchers are evaluating the safety and activity of barzolvolimab compared to a placebo in adults with cold induced urticaria ColdU or symptomatic dermographism SD who continue to have symptoms despite using H1-antihistamines. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand treatment options for these chronic skin conditions. Participants will first undergo a screening period lasting up to 4 weeks. Following this, there is a 24-week treatment phase where participants receive either barzolvolimab or a placebo. Those receiving barzolvolimab get a 450mg injection at the start, then 150mg every 4 weeks. After this, all participants receive 300mg barzolvolimab every 8 weeks for 28 weeks. Finally, there is a 16-week follow-up period where participants are observed without treatment. During the study, participants will complete daily symptom diaries and attend regular visits for assessments. Researchers will measure responses to provocation testing at various time points, clinical symptoms like itch and hives, and changes in temperature and friction thresholds. Quality of life related to dermatology will also be evaluated. Safety and tolerability are monitored throughout the study, which lasts over a year from screening to follow-up.

Age: 18Years +All GendersPhase 3
72 locations
A

Actively Recruiting

Researchers are evaluating the effects of AZD6793 in adults with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase IIb study compares two different doses of AZD6793 to placebo tablets to assess their efficacy and safety. The study is randomized, double-blind, placebo-controlled, and involves about 970 participants worldwide. Participants will be randomly assigned to one of three groups two different doses of AZD6793 or a matching placebo. The study lasts for 24 weeks, during which participants will take oral tablets of their assigned treatment. The trial aims to measure how well AZD6793 works to reduce COPD exacerbations compared to placebo. Throughout the study, participants will have regular assessments including lung function tests, symptom questionnaires, and blood tests to measure drug levels. Researchers will monitor the rate of COPD exacerbations, lung function changes, and symptom scores over 24 weeks. Safety and tolerability of the treatments will also be closely observed during this period.

Age: 40Years +All GendersPhase 2
367 locations
E

Actively Recruiting

Researchers are studying transthyretin amyloid cardiomyopathy ATTR-CM, a condition where abnormal clumps of the transthyretin TTR protein build up in the heart, affecting its ability to pump blood properly. This condition can be caused by age-related changes or genetic factors. The study aims to evaluate how switching from the drug tafamidis to acoramidis affects blood levels of the TTR protein in adults with this condition. Participants in the study will switch from tafamidis to acoramidis, taking acoramidis as two tablets twice daily by mouth for up to 6 months. During screening, participants continue tafamidis. The study involves a single group receiving acoramidis. Acoramidis works by stabilizing TTR, potentially reducing its breakdown and amyloid formation. Researchers will measure changes in TTR blood levels over time to understand if acoramidis increases TTR beyond levels achieved with tafamidis. Participants will undergo health reviews including medical history, ECGs, blood pressure, and heart rate assessments. Blood and urine samples will be collected at various points to monitor heart, kidney, and thyroid function, and other health markers. The study includes nine check-ins two at the study site screening and end of treatment, six home visits during the first month and at three months, and a final phone check-in. Participants may be involved for about eight months, with ongoing health monitoring throughout.

Age: 18Years - 90YearsAll GendersPhase 4
26 locations
E

Actively Recruiting

Researchers are evaluating depemokimab as a treatment for adults aged 40 to 80 years with moderate to severe chronic obstructive pulmonary disease COPD characterized by type 2 inflammation and frequent exacerbations. This Phase 3 trial aims to assess the efficacy and safety of depemokimab when added to standard care compared to a placebo with standard care. The study is sponsored by GlaxoSmithKline and focuses on reducing the rate of moderate to severe COPD exacerbations. Participants will receive either subcutaneous injections of depemokimab or placebo alongside their optimized inhaler therapies, which include inhaled corticosteroids, long-acting muscarinic antagonists, and long-acting beta2-adrenergic agonists, all maintained for at least six months prior to the study. The study uses a randomized, double-blind, parallel-group design and lasts for up to 104 weeks, during which participants continue their standard care while receiving the study treatments. Throughout the study, participants will be regularly monitored for COPD exacerbations and changes in respiratory symptoms using validated tools like the St. Georges Respiratory Questionnaire and the Evaluating Respiratory Symptoms in COPD score. Researchers will also track emergency visits or hospitalizations related to exacerbations. Safety assessments and efficacy measurements will be collected throughout the two-year period to evaluate the impact of depemokimab as an add-on treatment.

Age: 40Years - 80YearsAll GendersPhase 3
193 locations
D

Actively Recruiting

This research evaluates a new care approach for people living with dementia PlwD and their family caregivers in Germany, where about 1.8 million individuals have dementia. The study aims to test whether a specialized nurse-led care management program, supported by a mobile health app linking caregivers to experts and memory clinics, can help stabilize home care, reduce caregiver burden, and ease neuropsychiatric symptoms compared to usual care. The trial focuses on supporting both members of the caregiving pair, called a dyad, recognizing the high care demands and stress involved. Participants are divided into two groups. The intervention group receives personalized dementia care management for 12 months, tailored to their needs and monitored through the app. This app allows caregivers to communicate with care specialists anytime and provides ongoing data about caregiver health and stress to guide timely support. The control group continues with usual care, without this additional support. The intervention adapts in frequency and intensity based on the caregivers reported burden. During the study, participants will be regularly assessed on how stable their home care situation is, caregiver burden, and neuropsychiatric symptoms in the person with dementia, all measured at 12 months after starting. The research team collects data through the app and other evaluations to monitor health and provide appropriate support. The study is randomized and runs until late 2028, with the goal of improving long-term home care for families affected by dementia.

All AgesAll GendersPhase Not Applicable
12 locations

1-10 of 33

1